Dr Aesha Gandhi
My thesis aims to identify blood-based biomarkers, such as autoantibodies, HLA-genotype, TCR profiles, and tumour mutational burden (TMB), to predict immune-related adverse events (irAEs) in metastatic melanoma and lung cancer patients treated with immune-checkpoint inhibitors (ICIs). Using a large patient cohort and diverse analysis methods, including machine learning, I'm developing a predictive model that combines these biomarkers with clinical parameters. By improving risk prediction, my research seeks to enhance the safety and efficacy of ICI treatment for melanoma patients, addressing a critical need in personalised cancer care.